Goudsmit J
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Humane Retrovirologie, Meibergdreef 15, 1105 AZ Amsterdam.
Ned Tijdschr Geneeskd. 2001 Jun 30;145(26):1241-5.
Aids particularly affects people in developing countries, for whom the current forms of effective anti-retroviral therapy are both inaccessible and unaffordable. Just like smallpox in the past, the global aids epidemic can only be halted with a vaccine. It is estimated that the first generation aids vaccines will become available in about 10 to 15 years time. There is a sizeable chance that these vaccines will provide a certain degree of protection against aids and the spread of HIV. Yet in the short term, there is little chance of a vaccine which protects against infection from the HIV virus. The most important reason for this is that it has yet to be discovered how a vaccine can elicit antibodies which neutralise primary HIV isolates. The majority, if not all, first generation aids vaccines are expected to protect against aids on the basis of virus-specific T-cell immunity. The Netherlands has a key role in the aids vaccine programmes of the European Union (Eurovac) and is making important contributions to the International AIDS Vaccine Initiative.
艾滋病对发展中国家的人们影响尤为严重,因为他们无法获得且负担不起目前有效的抗逆转录病毒疗法。就像过去的天花一样,只有通过疫苗才能阻止全球艾滋病的流行。据估计,第一代艾滋病疫苗将在大约10到15年后问世。这些疫苗很有可能提供一定程度的艾滋病防护以及防止艾滋病毒传播。然而短期内,几乎没有可能研制出能预防艾滋病毒感染的疫苗。最重要的原因是尚未发现疫苗如何引发能中和原始艾滋病毒分离株的抗体。预计大多数(如果不是全部的话)第一代艾滋病疫苗将基于病毒特异性T细胞免疫来预防艾滋病。荷兰在欧盟的艾滋病疫苗计划(Eurovac)中发挥着关键作用,并为国际艾滋病疫苗倡议做出重要贡献。